Acebutolol
Administration
- Type: Beta blocker
- Dosage Forms: Cap: 200mg, 400mg
- Routes of Administration: Oral
- Common Trade Names: Sectral
Adult Dosing
Hypertension
- 400-800 mg PO bid
- Max: 1200 mg/day (800mg in elderly pts)
Ventricular arrhythmia
- 300-600 mg PO bid
- Max: 1200 mg/day (800mg in elderly pts)
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
- Pregnancy Rating: Possible risk of intrauterine growth restriction
- Lactation risk: Avoid during breastfeeding
Renal Dosing
- Adult:
- CrCl 25-50: Decrease dose 50%
- CrCl <25: Decrease dose 75%
- HD/PD: No supplement
- Pediatric: Not defined
Hepatic Dosing
- Adult: Caution advised
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Sinus bradycardia
- 2nd or 3rd degree AV block
- Heart failure, uncompensated
- Cardiogenic shock
- Sick sinus syndrome w/o pacemaker
- Breastfeeding
- Avoid abrupt withdrawal
Adverse Reactions
Serious
- CHF
- Bradycardia, severe
- Heart block
- Angina, MI if abrupt discontinuation
- Ventricular arrhythmia if abrupt discontinuation
- Raynaud phenomenon
- Bronchospasm
- Lupus erythematosus
Pharmacology
- Half-life: 3-4 hours (8-13h diacetolol)
- Metabolism: Liver; Production of active metabolite (diacetolol)
- Excretion: Bile/feces/gut wall 50-60%; Urine 30-40% (12-29% unchanged)
Mechanism of Action
- Selectively antagonizes beta-1 adrenergic receptors
- Class II antiarrhythmic
Comments
See Also
References
- Acebutolol hydrochloride [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; January 2016
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online ahead of print October 30, 2017]. Circulation. 2017. doi: 10.1161/CIR.0000000000000549. [PubMed 29084731]
- American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125(2):521-525. [PubMed 25611642]
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.